Alkylation of cysteine 468 in stat3 defines a novel site for therapeutic development

ACS Chemical Biology

Volumn 6, Issue 5, 2011, Pages 432-443

  Buettner, Ralf ^a   Corzano, Renzo ^a   Rashid, Rumana ^a   Lin, Jianping ^a   Senthil, Maheswari ^a   Hedvat, Michael ^a   Schroeder, Anne ^a   Mao, Allen ^a   Herrmann, Andreas ^a   Yim, John ^a   Li, Hongzhi ^a   Yuan, Yate Ching ^a   Yakushijin, Kenichi ^a   Yakushijin, Fumiko ^a   Vaidehi, Nagarajan ^a   Moore, Roger ^a   Gugiu, Gabriel ^a   Lee, Terry D ^a   Yip, Richard ^a   Chen, Yuan ^a   Jove, Richard ^a   Horne, David ^a   Williams, John C ^a   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYSTEINE; NSC 368262; PROTEIN INHIBITOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL NUCLEUS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ALKYLATION; AMINO ACID SEQUENCE; AMINOPYRIDINES; ANIMALS; APOPTOSIS; BENZODIOXOLES; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HELA CELLS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MASS SPECTROMETRY; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR;

EID: 79957510134     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb100253e     Document Type: Conference Paper

References (38)

1. Darnell, J. E., Jr. (1997) STATs and gene regulation Science 277, 1630-1635 (Pubitemid 27446219)
2. Ihle, J. N. (1996) STATs: signal transducers and activators of transcription Cell 84, 331-334 (Pubitemid 26058558)
3. Pellegrini, S. and Dusanter-Fourt, I. (1997) The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs) Eur. J. Biochem. 248, 615-633 (Pubitemid 27400015)
4. Bromberg, J. and Darnell, J. E., Jr. (2000) The role of STATs in transcriptional control and their impact on cellular function Oncogene 19, 2468-2473 (Pubitemid 30339202)
5. Decker, T. and Kovarik, P. (1999) Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins Cell. Mol. Life Sci. 55, 1535-1546 (Pubitemid 29445819)
6. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264, 1415-1421 (Pubitemid 24217131)
7. Bromberg, J. F., Fan, Z., Brown, C., Mendelsohn, J., and Darnell, J. E., Jr. (1998) Epidermal growth factor-induced growth inhibition requires Stat1 activation Cell Growth Differ. 9, 505-512 (Pubitemid 28345907)
8. Liddle, F. J., Alvarez, J. V., Poli, V., and Frank, D. A. (2006) Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants Biochemistry 45, 5599-5605 (Pubitemid 43673190)
9. Wenta, N., Strauss, H., Meyer, S., and Vinkemeier, U. (2008) Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations Proc. Natl. Acad. Sci. U.S.A. 105, 9238-9243
10. Li, L. and Shaw, P. E. (2006) Elevated activity of STAT3C due to higher DNA binding affinity of phosphotyrosine dimer rather than covalent dimer formation J. Biol. Chem. 281, 33172-33181 (Pubitemid 46036698)
11. Stancato, L. F., David, M., Carter-Su, C., Larner, A. C., and Pratt, W. B. (1996) Preassociation of STAT1 with STAT2 and STAT3 in separate signalling complexes prior to cytokine stimulation J. Biol. Chem. 271, 4134-4137 (Pubitemid 26070511)
12. Lin, J., Buettner, R., Yuan, Y. C., Yip, R., Horne, D., Jove, R., and Vaidehi, N. (2009) Molecular dynamics simulations of the conformational changes in signal transducers and activators of transcription, Stat1 and Stat3 J. Mol. Graph. Model. 28, 347-356
13. Kretzschmar, A. K., Dinger, M. C., Henze, C., Brocke-Heidrich, K., and Horn, F. (2004) Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells Biochem. J. 377, 289-297 (Pubitemid 38142184)
14. Yu, H. and Jove, R. (2004) The STATs of cancer-new molecular targets come of age Nat. Rev. Cancer 4, 97-105 (Pubitemid 38198738)
15. Buettner, R., Mora, L. B., and Jove, R. (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention Clin. Cancer Res. 8, 945-954 (Pubitemid 35177340)
16. Bowman, T., Garcia, R., Turkson, J., and Jove, R. (2000) STATs in oncogenesis Oncogene 19, 2474-2488 (Pubitemid 30339203)
17. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., and Darnell, J. E., Jr. (1999) Stat3 as an oncogene Cell 98, 295-303 (Pubitemid 29380565)
18. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., and Darnell, J. E., Jr. (1996) Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma Proc. Natl. Acad. Sci. U.S.A. 93, 7673-7678 (Pubitemid 26277095)
19. Becker, S., Groner, B., and Muller, C. W. (1998) Three-dimensional structure of the Stat3beta homodimer bound to DNA Nature 394, 145-151 (Pubitemid 28325960)
20. Herrmann, A., Vogt, M., Monnigmann, M., Clahsen, T., Sommer, U., Haan, S., Poli, V., Heinrich, P. C., and Muller-Newen, G. (2007) Nucleocytoplasmic shuttling of persistently activated STAT3 J. Cell Sci. 120, 3249-3261 (Pubitemid 350018416)
21. Hintzen, C., Haan, C., Tuckermann, J. P., Heinrich, P. C., and Hermanns, H. M. (2008) Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression J. Immunol. 181, 7341-7349
22. Pranada, A. L., Metz, S., Herrmann, A., Heinrich, P. C., and Muller-Newen, G. (2004) Real time analysis of STAT3 nucleocytoplasmic shuttling J. Biol. Chem. 279, 15114-15123 (Pubitemid 38618906)
23. Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L., Jove, R., McLaughlin, M. M., Lawrence, N. J., Sebti, S. M., and Turkson, J. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity Proc. Natl. Acad. Sci. U.S.A. 104, 7391-7396 (Pubitemid 47185916)
24. Dixon, J. M. (2002) Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment Exp. Rev. Anticancer Ther. 2, 267-275 (Pubitemid 34679482)
25. Hong, Y., Yu, B., Sherman, M., Yuan, Y. C., Zhou, D., and Chen, S. (2007) Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase Mol. Endocrinol. 21, 401-414 (Pubitemid 46184893)
26. Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., Rettig, W. J., Meyerson, M., Solca, F., Greulich, H., and Wong, K. K. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27, 4702-4711
27. Spicer, J. F. and Rudman, S. M. (2010) EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992, Target Oncol.
28. Ahmad, R., Raina, D., Meyer, C., Kharbanda, S., and Kufe, D. (2006) Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179 J. Biol. Chem. 281, 35764-35769 (Pubitemid 46041307)
29. Shishodia, S., Sethi, G., Konopleva, M., Andreeff, M., and Aggarwal, B. B. (2006) A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells Clin. Cancer Res. 12, 1828-1838
30. Schrödinger (2005) Maestro, 7.5 ed., New York.
31. Connolly, M. L. (1983) Solvent-accessible surfaces of proteins and nucleic acids Science 221, 709-713
32. Herrmann, A., Sommer, U., Pranada, A. L., Giese, B., Kuster, A., Haan, S., Becker, W., Heinrich, P. C., and Muller-Newen, G. (2004) STAT3 is enriched in nuclear bodies J. Cell Sci. 117, 339-349 (Pubitemid 38128911)
33. Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A., and Jove, R. (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells Oncogene 20, 2499-2513 (Pubitemid 32531347)
34. Wagner, B. J., Hayes, T. E., Hoban, C. J., and Cochran, B. H. (1990) The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter EMBO J. 9, 4477-4484 (Pubitemid 120026005)
35. Yu, C. L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., and Jove, R. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein Science 269, 81-83
36. Hedvat, M., Jain, A., Carson, D. A., Leoni, L. M., Huang, G., Holden, S., Lu, D., Corr, M., Fox, W., and Agus, D. B. (2004) Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma Cancer Cell 5, 565-574 (Pubitemid 38748918)
37. Kim, P. K., Armstrong, M., Liu, Y., Yan, P., Bucher, B., Zuckerbraun, B. S., Gambotto, A., Billiar, T. R., and Yim, J. H. (2004) IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo Oncogene 23, 1125-1135 (Pubitemid 38269966)
38. Li, L., Cheung, S. H., Evans, E. L., and Shaw, P. E. (2010) Modulation of gene expression and tumor cell growth by redox modification of STAT3 Cancer Res. 70, 8222-8232